#50: Acuvue Oasys 1-Day: New Product Launch, Exclusive Interviews

AdminWolf

Site Administrator & Tech Lead
Staff member
Feb 24, 2001
16,639
3,294
113
School/Org
University of Michigan Medical School
City
Lake Oswego
State
OR
** An ODwire.org Exclusive **

Johnson & Johnson Vision Care (JJVC) is rolling out their newest lens, Acuvue Oasys 1-Day, and I was able to go on-site to Jacksonville, FL to the company's corporate headquarters to get a "sneak peek" at the lens being made, and interview key staff members at JJVC about the new product.

The degree of secrecy behind this product (in development for 10 years!) was unusual, so much so that I was left guessing nearly up until interview time as to what my trip was going to be about.

After my visit I came to understand why. The company feels this lens is going to have a significant impact on the market, thus the need for these extraordinary precautions.

Enjoy these brief interviews, and please do ask questions in the discussion thread below.


Part 1: Introduction

In this first interview with Laura Angelini, President, Johnson & Johnson Vision Care, Inc. and Dr. Millicent Knight, Head of Professional Affairs, JJVC we talk about Acuvue Oasys 1-Day, what makes this product launch different from all others, and what it will mean to clinicians and patients.


Part 2: Science & Lens Design

Dr. Dave Turner, Senior Director of World Wide R&D at JJVC, and Bart Johnson, Senior Manager R&D at JJVC Jacksonville discuss the science behind the lens, its design, and comparison to other products such as DT1.


Part 3: Manufacturing & Quality Control

You may not think a lot about where contact lenses come from, but ponder this: a daily disposable needs 30x the number of lenses that a monthly does.

How does one scale up to consistently produce a new product like this? In a wide parameter range, no less? (Acuvue Oasys 1-Day will cover +8 to -12 at launch, and nearly 20,000 fit sets will be produced within the first several months, so all fitters that want to will have a crack at it.)

I got a tour of the production facility and was able to interview Tim Ryan, JJVC's Plant Manager, and Mike Alleva, World Wide VP of Operations to talk about this new production lines & how they have been able to produce the lens in the quantities that will be needed right out of the chute.


MORE DETAILS INCLUDING LAUNCH DATES IN THE THREAD BELOW... Enjoy!
 
  • Like
Reactions: Lisa Heuer
Just to give you a little further color & background --

On my way to do those interviews (what have I gotten myself into....)



The tour of the production facility was remarkable, if you're into that sort of thing (I like visiting all kinds of factories, what can I say... everyone needs a hobby, right?)

IMG_1513.jpg



Each production line of the 1-Day Oasys was about the length of a tractor-trailer. The raw materials (virgin plastics, etc..) came in on one side, and finished 90 packs popped out the other. No human hands involved.

Indeed, the thing that struck me most about it was the lack of people on each line -- Robots were doing the hard work of actually producing the lenses.

IMG_1516.jpg


As you heard in the interview, each line requires 4 highly skilled human beings to keep it running, but the grunt-work and QA is handled by creatures much better suited to high-volume, consistent production than people.

So I got to see in a very personal way what manufacturing in the US looks like these days -- this is what companies do if they don't want to outsource. It is very high-tech, and it requires employees with the skills to match.

One incidental fact that they mentioned to me is that a large proportion of their production employees (50%? maybe more?) are ex-military, which isn't surprising given the Jacksonville location and the need for people who can keep complicated machines running.

I tried to take as many pictures as I could to give everyone a sense of the place, but I didn't want to get thrown into Vistakon Jail (i'm assuming they have one in the basement, like Disney, right?)

One thing I can say is that there was a palpable difference around this product launch vs. the others that i've covered before -- I think they are seeing this lens as a potential game-changer in many ways.

I know that 1-Day penetration in the US lags the rest of the developed world, and my gut tells me that this product may cause that dynamic to shift a bit.

So... that's my brief report from the field. Ask any questions about Oasys 1-Day in this thread!
 
Last edited:
  • Like
Reactions: Lisa Heuer
Oh, forgot to mention my usual disclaimer/financial disclosures for this trip: I paid for my own travel, car, hotel, gas, etc... The folks at JJVC took me out for dinner one night.

If you've got any more questions about the trip, the product, etc... ask away.

ad
 
How are they positioning this lens in relation to their other 1 day products? What about UPP? Sorry if this was covered in the interviews, it is zero dark thirty here and no one dare make a sound and wake up their mother...
 
Adam ... I'm intrigued by the new lenses. If the lens maintains consistency throughout the day, do you think it might be used for patients that have severe dry eye problems where nothing else has helped in the past? From the sounds of it, I'm sure that the lens may be used as a bandage lens. I listened to your interviews, but I don't think this was addressed.
 
  • Like
Reactions: Rita E Niyigena
HOW DID ODWIRE GET THE SCOOP ON THIS!?

(I heard that the TruEye was dead, but I didn't know what was going to replace it.)

It looks like the Dodge Viper-vs.-Chevy Corvette-vs.-Ford Shelby Cobra top-end performance product competition goes on. (DT-1 vs. Ultra vs. Oasys 1-day). I still call it the "hyper-humectant" class of contacts.

Just make the UPP somewhat plausible, please...
 
Sales rep came by a week or two ago.

Had me sign the form. I immediately figured out what it was.

Looking forward to the parameters. Need that plus lens.
 
HOW DID ODWIRE GET THE SCOOP ON THIS!?

(I heard that the TruEye was dead, but I didn't know what was going to replace it.)

It looks like the Dodge Viper-vs.-Chevy Corvette-vs.-Ford Shelby Cobra top-end performance product competition goes on. (DT-1 vs. Ultra vs. Oasys 1-day). I still call it the "hyper-humectant" class of contacts.

Just make the UPP somewhat plausible, please...

Adam may be slow answering questions this morning.

He worked overnight breaking this story to be released at 6am ET(3am PT).

Secrecy was key as far as J&J Vision Care is concerned. ODwire.org is a very tight operation. Adam was the only one knowing the details. I was kept out of the loop to be certain I did not slip up unintentionally.

Ask questions and I'm certain Adam will fill in the details.
 
I listened to all three interviews. Great information. Johnson& Johnson Vision Care is serious about being the leader in the contact lens field. They have made a mega investment.

There are many unanswered questions. Ask away this is the place.
 
How are they positioning this lens in relation to their other 1 day products? What about UPP? Sorry if this was covered in the interviews, it is zero dark thirty here and no one dare make a sound and wake up their mother...
Hi Ryan, I'll try to answer as best I can, but for an official answer i'll probe my sources at JJ.

1) UPP, yes.

2) This is a premium lens, the studies were head-to-head against DT1 where according to JJ it compared favorably. However they are pricing it lower, and producing it in large quantities out of the gate -- this is what interview #3 was about, they wanted to show me the scale of the manufacturing operation
 
HOW DID ODWIRE GET THE SCOOP ON THIS!?

(I heard that the TruEye was dead, but I didn't know what was going to replace it.)

It looks like the Dodge Viper-vs.-Chevy Corvette-vs.-Ford Shelby Cobra top-end performance product competition goes on. (DT-1 vs. Ultra vs. Oasys 1-day). I still call it the "hyper-humectant" class of contacts.

Just make the UPP somewhat plausible, please...

Someone at the company reached out to me, told me they had something major brewing and wanted ODwire.org members to know about it in as detailed a way as possible, no rumor mills. They couldn't tell me exactly what it was -- which was highly unusual. So... I took a chance and got on a plane, figuring it was going to be important. (Nothing ventured, nothing gained, right?) :)

The competition for the lens is DT1 indeed, but they are pricing it below DT1, and have the full parameter ranges ready from the start. And as you heard in the interview, 20,000 kits. So no fighting over fit sets, etc...

A lot of the cost of the development of this lens was R&D -- for manufacturing. They wanted to make sure that they could make enough of the product in wide ranges.
The plant was a shock, i had visited there with Howard Purcell maybe 12 years ago (?), this was a different animal entirely. The building was built from scratch, the level of automation was surprising -- more robots than people! :)
 
(I heard that the TruEye was dead, but I didn't know what was going to replace it.)

BTW --
"TruEye is not being discontinued and has no plans of being discontinued. We will continue to have 3 daily disposable options to meet different patient needs."
 
Adam ... I'm intrigued by the new lenses. If the lens maintains consistency throughout the day, do you think it might be used for patients that have severe dry eye problems where nothing else has helped in the past? From the sounds of it, I'm sure that the lens may be used as a bandage lens. I listened to your interviews, but I don't think this was addressed.

Not addressed, but as far as I can tell they are targeting the same segment as DT1, so i'd be surprised if people didn't try using the lens in a similar way.
 
I'd kill the TruEye, if it were me.

I'm a JnJunkie. I think I could run their company.

Product line:

HEMA:
Acuvue 2
Acuvue 1-day (without "moist" or as little as possible)
Acuvue 1-day T
Acuvue 1-day MF

SiHy:
Oasys
Oasys Astig
Oasys MF (redesigned, please)
Oasys 1-day

UPP on all except AV2

Simple, simon. Maybe I'll get a plane ride.
 
  • Like
Reactions: Diane Robbins-Luce
More tidbits:
  • Official National Launch date is 11/2
  • JJVC start shipping out kits beginning in October to achieve 20,000 total kits as quickly as possible.
  • Ask your rep for a kit starting today... "[we want] to ensure we get this important Brand into the hands of doctors who are excited to start fitting."
Ask reps for kits to ensure we get this important Brand into the hands of doctors who are excited to start fitting."
 
I wonder what JnJ perceives to be the three market segments?

I will ask. During my trip, I deduced that there are several ODwire.org docs who have had access to this lens during its testing (not a surprise, since about half of all docs are here), but were unable to talk about it -- hopefully with our announcement they will be given the latitude to talk about their experience with the lens so far.
 
My rep came by the other day and asked for my Rx so she could get me trials of a new one day lens that is coming out but said she couldn't tell me much about it. This must be it. I assumed they were trying to compete with the DT1. Looking forward to getting it.

P.S. the video you posted requires a password, so I couldn't watch it.
 
My rep came by the other day and asked for my Rx so she could get me trials of a new one day lens that is coming out but said she couldn't tell me much about it. This must be it. I assumed they were trying to compete with the DT1. Looking forward to getting it.

P.S. the video you posted requires a password, so I couldn't watch it.
video works fine here, can everyone else see it? an exciting commute ;)
 
Hi Adam,

I had the chance to work on a pre-market study on this lens and had access to it. We took existing CL wearers, whether they were current frequent replacement or daily disposable wearers, and tracked their comfort and vision ratings for a week. The study protocol was unique in that we gave a small number of subjects Apple iWatches. The subjects used the iWatches to complete a survey every hour while awake and wearing their lenses- fishing for any complaints of discomfort or dry eye. We then refit them into the AV Oasys 1-day and tracked the same metrics the following week.

It was interesting to see what we all know about contact lens wear in general unfold in real time- that the end of the day is more of a challenge than the beginning of the day. The new lens definitely delivered on attacking end of day dryness. Although I do not have the results of the study over all of the locations, I know that for my 15 subjects, there was a significant difference. Thirteen of my 15 subjects expressed a desire to purchase the new lens. One did not like the environmental idea of using a DD due to packaging. When I brought this up to Cris Snyder at J&J, she had a great retort. She said, "look at the environmental impact of dumping tons and tons of MPS solution down the drain and ultimately into the water supply. Oh, and the packaging is all recyclable." -something to think about. The other subject was a gal in my office who had poor initial comfort, likely solution related. The study did not allow us to troubleshoot.

Overall, I am excited to try it in real life in my office (don't have a fitting set yet). By the way, I consult for 3 of the big 4 (as well as a bunch of other companies), so am careful when it comes to talking about product. But, I like new stuff that propels the profession forward.

Jeffrey Sonsino, O.D., F.A.A.O.
Optique Eyecare & Eyewear
Nashville, TN
Diplomate, CCLRT
American Academy of Optometry
 
  • Like
Reactions: Ryan Mckinnis
Hi Adam,

I had the chance to work on a pre-market study on this lens and had access to it. We took existing CL wearers, whether they were current frequent replacement or daily disposable wearers, and tracked their comfort and vision ratings for a week. The study protocol was unique in that we gave a small number of subjects Apple iWatches. The subjects used the iWatches to complete a survey every hour while awake and wearing their lenses- fishing for any complaints of discomfort or dry eye. We then refit them into the AV Oasys 1-day and tracked the same metrics the following week.

Jeff -- thanks for this! I knew the protocol for the study was different, I had no idea the patients got Apple Watches! (they didn't get to keep 'em, right? :) )

Curious about the material -- did it seem significantly different to you than the original Oasys?
 
The subjects used the iWatches to complete a survey every hour while awake and wearing their lenses- fishing for any complaints of discomfort or dry eye. We then refit them into the AV Oasys 1-day and tracked the same metrics the following week.

Hi Jeff,

Did the subject wear their old lenses the first week or began with fresh lenses?

did the subjects know they were wearing a brand new product the second week or told it's just another lens presently in use. Placebo effect for bias for something new versus same old must be considered.

Ask married folks.;)
 
Adam,

Unfortunately, they did not get to keep the iWatches. I'm sure some compliance officer in some office crushed that idea.

Paul,

We had our subjects start with new (habitual) lenses for the first week. If they were out, we gave them trials. But we had a significant number habitually wearing DD, as is the demographic of my practice. There were a significant number wearing other AV products and other SiHy DD lenses.

The only thing we told them is that we are evaluating a new DD lens. The majority of our patient population are in the healthcare field or in academia due to our proximity to a major research university. They seem to have no fear telling us that something new stinks. But, the placibo effect is that same if you are evaluating a patient in the chair for a regular eye exam. How the doctor talks about the lens has a very significant effect on the outcome. "We have a new lens that lets way more oxygen through to the eye. Do you want to try it or stay in your old one that was great technology... in 1984?"
 
As an Oasys fan I'm excited to try it and will run it through the ringer. The guys in R&D did a nice job, an excellent job, but I wish they would have gotten into more weedy detail regarding the chemistry and especially the differences and similarities between the Oasys One Day lens and the traditional Oasys.

I'm appreciative of Adam's paying for his own way and making his best effort to be impartial.

Oh, and when we are testing out new materials/designs on our patients, it's important to be impartial and not let our speech influence the outcome our patients' experience with the lens compared to what they are currently using. As Dr. Sonsino pointed out, it clearly matters and it is incumbent on us as clinicians to limit the placebo effect. -Charlie
 
I hope this is another winner. I have wished for a better wholesale and UPP cost on the DT1. I will also be watching carefully how UPP holds up (if 1800 will trash that immediately) and if there are "special" packs and deals for box stores. The special packages of Oasys that exceed a year supply and undercut UPP for some big box retailers is still leaving a bad taste in my mouth for Vistakon.
 
As an Oasys fan I'm excited to try it and will run it through the ringer. The guys in R&D did a nice job, an excellent job, but I wish they would have gotten into more weedy detail regarding the chemistry and especially the differences and similarities between the Oasys One Day lens and the traditional Oasys.

I'm appreciative of Adam's paying for his own way and making his best effort to be impartial.

Thanks, Charlie. I am really thankful to JJVC for giving me the opportunity this time around. They stepped out on a limb by:

1) contacting me
2) trusting that i'd keep their confidential info safe (I didn't even tell Paul the details of what I was up to ;-) )
3) opening up their organization to let me talk to the people who were instrumental in creating and pushing the new lens out the door.

I'd asked their marketing folks to just line up a few people for me to talk to, I had no idea that we'd get as high-level as the President & as nitty-gritty as the guys responsible for the running the lens production facility. It was a good mix.

My hope that I can do something similar for future product releases, the hard part is both getting the access AND being ready at a moment's notice to drop what i'm doing and get the scoop.
 
What about lens quality and reproducibility? The TruEye was plagued with issues. As a person who actually wore the lens I found that nearly 25% of my lenses were warped or some other issue causing vision distortion. Replacing the lens with another TruEye would usually fix the problem but it happened more than once where I would get two in a row that were bad. I had heard a rumor that the TruEye had a 25-30% defect rate coming off the line!
 
I hope its not just acuvue advance plus:eek:
 
What about lens quality and reproducibility? The TruEye was plagued with issues. As a person who actually wore the lens I found that nearly 25% of my lenses were warped or some other issue causing vision distortion. Replacing the lens with another TruEye would usually fix the problem but it happened more than once where I would get two in a row that were bad. I had heard a rumor that the TruEye had a 25-30% defect rate coming off the line!

As they say, "the proof of the pudding is in the eating", so we'll all have to see what happens as the Oasys 1-Day rolls out.

But listen to interview #3; those were the two men responsible for the manufacturing of this lens.

They were extremely confident in their new production lines, to the point that they are stockpiling inventory to ensure that there will be sufficient production right at launch, across all the parameter ranges (+8 / -12). Which is unusual, IMO. As are the 20,000 fit sets. The mantra was repeated to me numerous times during my visit: "Anyone who wants to fit this lens will be able to fit this lens."
 
What about lens quality and reproducibility? The TruEye was plagued with issues. As a person who actually wore the lens I found that nearly 25% of my lenses were warped or some other issue causing vision distortion. Replacing the lens with another TruEye would usually fix the problem but it happened more than once where I would get two in a row that were bad. I had heard a rumor that the TruEye had a 25-30% defect rate coming off the line!

That was my experience with TruEye as well. For something that costs as much as it does, the quality control was terrible.

I currently wear Total1 and I notice occasional lemons. Usually the problem is a lens that is inserted inside out. But, I've had 2 occasions in the last month where one package contained 2 lenses.
 
JJVC issued a press release today about the product, I've put it here so you can discuss:

JOHNSON & JOHNSON VISON CARE, INC. LAUNCHES NEW LENS WITH A TEAR-INFUSED DESIGN

ACUVUE OASYS® Brand Contact Lenses 1-Day with HydraLuxeTM Technology help support the natural tear film and was preferred overall to the competition in a head-to-head study1

JACKSONVILLE, Fla., September 10, 2015: Johnson & Johnson Vision Care, Inc. announced the launch of a new lens with a tear-infused design, ACUVUE OASYS® Brand Contact Lenses 1-Day with HydraLuxeTM Technology, to provide excellent comfort and vision throughout a day full of activities.

For a majority of contact lens wearers (59 percent)2, contact lens performance declines throughout the day. This rate of decline correlates with the number of activities the contact lens wearer performs in a day, and research shows that a full day of activities can lead to eye fatigue or the feeling of tired eyes.

“We honed in on the human insight that patients need contact lenses that can keep up with the daily demands of today’s modern life,” said Millicent Knight, OD, vice president of professional affairs, Johnson & Johnson Vision Care, Inc. North America. “This includes looking at computers, smartphones, or even living in air-conditioned buildings. Each one is a potential contributor to destabilizing the natural tear film throughout the course of the day, causing a decline in contact lens performance.”3

ACUVUE OASYS® 1-Day with HydraLuxeTM Technology is designed to help keep contact lens wearers comfortable throughout their demanding days. There are four key technology advances to help address this unmet patient need:

  •  Tear-infused material, complementing the natural tear film with an enhanced network of tear-like molecules, that integrates with contact lens wearers’ own tear film each day

  •  Electrolyte-balanced packaging solution to mimic human tears

  •  Enlarged optics to help wearers to see clearly even when their pupils may be enlarged due to

    low-light

  •  Increased lens diameter to ensure full corneal limbus coverage during blinking.

    “Tears are the key to this innovation,” said Peter Shen, vice president, Worldwide Research & Development, Johnson & Johnson Vision Care, Inc. “We know tears are essential to provide a smooth optical surface, provide oxygen to the cornea, and moisturize and lubricate the eyes to facilitate natural blinking. The tear-like molecules in ACUVUE OASYS® 1-Day with HydraLuxeTM Technology mimic mucins, which lubricate and moisturize the eye and help support a stable tear film even through our most demanding days.”

    ACUVUE OASYS® 1-Day with HydraLuxeTM Technology works consistently throughout the day to help support a stable tear film. In a head-to-head comparison with Dailies Total1® in 119 people who wore both lenses for a week, ACUVUE OASYS® 1-Day with HydraLuxeTM Technology was preferred 2:1 overall, with excellent performance in comfort, vision and handling, including ease of removal.1 The ACUVUE OASYS® 1-Day has the highest level of UV blocking available in a contact lens to help protect the eye
from the transmission of the sun’s harmful rays.†‡ ACUVUE OASYS® 1-Day with HydraLuxeTM Technology will launch worldwide beginning in 2016.

A New Design to Provide Superior Experience

They EYE-INSPIREDTM Design behind ACUVUE OASYS® 1-Day with HydraLuxeTM Technology was to develop a tear-like lens, not simply water based, in order to help support a patient’s tear film each day. Unlike water-gradient designs, a tear-infused contact lens is smoother at the surface, has a uniform composition throughout the lens and has consistent performance over time. Additionally, the lens was designed with an increased diameter to ensure full corneal limbus coverage during blinking and includes enlarged optics to help cover larger pupils in low lighting conditions.

EYE-INSPIREDTM Design

For more than 30 years, Johnson & Johnson Vision Care, Inc. has focused exclusively on improving vision through quality contact lenses, never compromising on its goal to create technologies that make meaningful differences in people’s lives.

A deep understanding of patient lifestyle needs as well as those of eye care professionals has driven R&D to create innovative solutions designed to complement the natural function of the eye. By developing contact lenses based on a deep understanding of how the eye works, the ACUVUE® Brand strives to maximize the eye’s natural wellbeing during contact lens wear, and give patients and eye care professionals an exceptional experience.

About Johnson & Johnson Vision Care, Inc.

Johnson & Johnson Vision Care, Inc. is committed to creating life-long solutions to vision care needs. Since the ACUVUE® Brand made its debut in 1987 as the world’s first disposable soft contact lens, the company has repeatedly brought innovative, quality, and scientific advancements to the industry. Headquartered in Jacksonville, Florida, the company has some 3,000 employees worldwide. For more information, visit www.AcuvueProfessional.com.

###

page2image15992

Important Information for Contact Lens Wearers: ACUVUE® Brand Contact Lenses are available by

prescription only for vision correction. An eye care professional will determine whether contact lenses are

right for you. Although rare, serious eye problems can develop while wearing contact lenses. To help

avoid these problems, follow the wear and replacement schedule and the lens care instructions provided

by your eye doctor. Do not wear contact lenses if you have an eye infection, or experience eye

discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions

occurs, contact your eye doctor immediately. For more information on proper wear, care and safety, talk

to your eye care professional and ask for a Patient Instruction Guide, call 1-800-843-2020 or visit

Acuvue.com.

page2image26512

†Helps protect against transmission of harmful UV radiation to the cornea and into the eye.

page2image27680

: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. You should continue to use UV-absorbing eyewear as directed. NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities). UV-blocking contact lenses help provide protection

‡WARNING

against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-blocking contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your eye care practitioner for more information.

ACUVUE OASYS® with HydraLuxeTM Technology, 1-Day ACUVUE® MOIST Brand Contact Lenses and EYE-INSPIREDTM Design are registered trademarks of Johnson & Johnson Vision Care, Inc.

Third party trademarks used herein are trademarks of their respective owners.

For further information, contact:

Donna Lorenson Johnson & Johnson 732-524-5190 dlorens@ITS.JNJ.com

1 n=119, 4-7 days of 1-day wear. Preference results are among those with a preference.
2 Mathews K. et al. Exploring Variability in Soft Contact Lens Performance throughout the Day. Abstract. 2015 American Academy of Optometry (AAO) Annual Meeting. October 8, 2015.
3 Craig JP, Willcox MDP, Argueso P, et al. The TFOS International Workshop on Contact Lens Discomfort: Report of the Contact Lens Interaction with the Tear Film Subcommittee. Invest Ophthalmol Vis Sci. 2013; 54 (11):TFOS123-TFOS156.
 
Listened to all three recordings, and found all three pretty much lacking in any real information. Just a lot of company hype repeated over and over. What is the polymer? What are the crosslinking agents? What is the Dk/T? What is the modulus? None of that was even alluded to. I love it whenever we get a new product, and especially a daily, but how about some actual INFORMATION about it?
 
Listened to all three recordings, and found all three pretty much lacking in any real information. Just a lot of company hype repeated over and over. What is the polymer? What are the crosslinking agents? What is the Dk/T? What is the modulus? None of that was even alluded to. I love it whenever we get a new product, and especially a daily, but how about some actual INFORMATION about it?

I'll have more info for you shortly -- I've asked the company to provide as much info as they can around the technical aspect of the lens.
 
Adam,

Is this s'posed to be available to the public? On my computers, anyone can view by clicking on the link without logging in.
 
Adam,

Is this s'posed to be available to the public? On my computers, anyone can view by clicking on the link without logging in.

Just the first post in the thread should be, i'll go back and look again to make sure that is the case in this thread.

Unlike the rest of the site, the first post on the "radio" and "webinar" tabs are always visible to people without accounts, because they are just recordings of us doing performances -- so nothing 'confidential' there, i don't care if people mock my showmanship or professionalism :)

ad
 
New Sight Capital